Lung cancer trial aims to boost tumor shrinkage while protecting lungs

NCT ID NCT07418866

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new approach for advanced non-small cell lung cancer. It combines chemotherapy and immunotherapy with a special 'high-low mixed-dose' radiotherapy that gives a strong dose to large tumors and a lower dose to smaller ones. The goal is to shrink tumors faster and reduce lung damage. The study will enroll 70 people with advanced lung cancer that does not have certain genetic mutations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel, Cisplatin, 5-FU, Serplulimab (chemo-immunotherapy drugs) plus high-low mixed-dose radiotherapy
What this could lead to: If successful, this approach could improve tumor shrinkage and disease control in advanced lung cancer while reducing the risk of radiation-related lung inflammation.
What could go wrong: This is an early phase 2 trial with only 70 participants, so results may not apply broadly. The combination of treatments may still cause side effects like lung inflammation or other toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

More trials for these conditions

Other studies related to the condition(s) this trial covers.